Saqib Islam
Net Worth
Last updated:
What is Saqib Islam net worth?
The estimated net worth of Mr. Saqib Islam is at least $70,237,190 as of 2 Dec 2024. He owns shares worth $47,655,009 as insider, has earned $18,796,941 from insider trading and has received compensation worth at least $3,785,240 in SpringWorks Therapeutics, Inc..
What is the salary of Saqib Islam?
Mr. Saqib Islam salary is $946,310 per year as Chief Executive Officer & Director in SpringWorks Therapeutics, Inc..
How old is Saqib Islam?
Mr. Saqib Islam is 55 years old, born in 1970.
What stocks does Saqib Islam currently own?
As insider, Mr. Saqib Islam owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| SpringWorks Therapeutics, Inc. (SWTX) | Chief Executive Officer & Director | 1,014,368 | $46.98 | $47,655,009 |
What does SpringWorks Therapeutics, Inc. do?
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Saqib Islam insider trading
SpringWorks Therapeutics, Inc.
Mr. Saqib Islam has made 18 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 3,989 units of SWTX stock worth $166,936 on 2 Dec 2024.
The largest trade he's ever made was exercising 60,301 units of SWTX stock on 19 Jan 2021. As of 2 Dec 2024 he still owns at least 1,014,368 units of SWTX stock.
SpringWorks Therapeutics key executives
SpringWorks Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Badreddin Edris Ph.D. (38) Chief Operating Officer
- Dr. L. Mary Smith PH.D. (58) Chief Devel. Officer
- Mr. Daniel Pichl (42) Chief People Officer
- Mr. Francis I. Perier Jr., M.B.A. (65) Chief Financial Officer
- Mr. Herschel S. Weinstein J.D. (69) Gen. Counsel & Sec.
- Mr. Saqib Islam (55) Chief Executive Officer & Director